Targeted drug delivery using genetically engineered diatom biosilica.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Targeted cancer therapy aims to eliminate cancerous cells while sparing healthy ones.
• Current nanoporous silica drug delivery systems often rely on toxic and expensive chemicals for production.
• There is a need for sustainable and effective drug delivery vehicles in oncology.

Purpose of the Study:

• To utilize diatom-derived nanoporous biosilica as a drug delivery vehicle for cancer treatment.
• To engineer biosilica for targeted delivery of chemotherapeutic drugs to specific cancer cell types.
• To evaluate the efficacy of antibody-conjugated biosilica in killing cancer cells and regressing tumors.

Main Methods:

• Genetically engineered the diatom Thalassiosira pseudonana to display protein G on biosilica surfaces.
• Functionalized biosilica with cell-targeting antibodies for specific cancer cell recognition.
• Loaded drug-encapsulated nanoparticles onto the antibody-conjugated biosilica.
• Tested targeted killing of neuroblastoma and B-lymphoma cells in vitro and tumor regression in a mouse xenograft model.

Main Results:

• Engineered biosilica successfully targeted and killed neuroblastoma and B-lymphoma cancer cells.
• Antibody-conjugated, drug-loaded biosilica demonstrated selective cancer cell destruction.
• In vivo studies showed significant tumor growth regression in a neuroblastoma mouse model.

Conclusions:

• Genetically engineered diatom biosilica serves as an effective and versatile platform for targeted anticancer drug delivery.
• This approach offers a sustainable alternative to synthetic silica materials, utilizing biocompatible biosilica.
• The 'biosilica backpack' concept shows promise for delivering poorly water-soluble anticancer drugs to tumor sites.